Mosunetuzumab在老年复发/难治性滤泡性淋巴瘤患者中有效且耐受良好:一项I/II期研究的亚组分析
该I/II期研究亚组分析纳入218例复发/难治性B细胞非霍奇金淋巴瘤患者(≥65岁102例,<65岁116例)及90例复发/难治性滤泡性淋巴瘤患者(≥65岁30例,<65岁60例),评估Mosunetuzumab的疗效与安全性。老年滤泡性淋巴瘤患者总缓解率86.7%、完全缓解率70.0%,中位无进展生存期17.9个月。
要点
- 老年B细胞非霍奇金淋巴瘤患者细胞因子释放综合征发生率33.3%,低于年轻患者的44.8%。
- 老年复发/难治性滤泡性淋巴瘤患者总缓解率86.7%、完全缓解率70.0%,数值上高于年轻患者的76.7%和55.0%。
- 老年患者中位无进展生存期17.9个月,至下次治疗时间未达到。
核心结论
- Mosunetuzumab在复发/难治性滤泡性淋巴瘤各年龄组中均有效且耐受良好。
- 需要进一步研究以评估Mosunetuzumab在老年B细胞非霍奇金淋巴瘤患者中的安全性和有效性。
研究设计与样本
- I/II期研究亚组分析,纳入I期扩展队列(NCT02500407)中218例复发/难治性B细胞非霍奇金淋巴瘤患者(≥65岁102例,<65岁116例)。
- 进一步评估关键队列中90例复发/难治性滤泡性淋巴瘤患者(≥65岁30例,<65岁60例)。
主要发现
- B细胞非霍奇金淋巴瘤患者最常见不良事件为细胞因子释放综合征,老年组发生率33.3%,低于年轻组的44.8%。
- 严重不良事件老年组为45.1%,与年轻组的46.6%相似。
- 复发/难治性滤泡性淋巴瘤患者中,老年组总缓解率86.7%、完全缓解率70.0%,数值上高于年轻组的76.7%和55.0%。
- 老年组中位无进展生存期17.9个月、至下次治疗时间未达到,年轻组分别为12.0个月和18.1个月。
局限性
- 需要进一步研究以评估Mosunetuzumab在老年B细胞非霍奇金淋巴瘤患者中的安全性和有效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A high unmet need for novel, safe and effective therapies exists among older patients with non-Hodgkin lymphoma (NHL). We report safety and efficacy of mosunetuzumab in a subgroup analysis of a phase I/II study, which examined the prognostic impact of age in 218 patients with relapsed/refractory (R/R) B-cell NHL (B-NHL; ≥65 years, n = 102; <65 years, n = 116) from the phase I expansion cohort (NCT02500407) and further evaluated 90 patients with R/R follicular lymphoma (FL; ≥65 years, n = 30; <65 years, n = 60) from the pivotal cohort. The most common adverse event (AE) was cytokine release syndrome, occurring less frequently in older versus younger (33.3% vs. 44.8%) patients with B-NHL. Serious AEs were similar in older versus younger patients (45.1% vs. 46.6%). For patients with R/R FL, overall and complete response rates were numerically higher in older (86.7% and 70.0%, respectively) versus younger (76.7% and 55.0%) patients. Median progression-free survival and time-to-next treatment were 17.9 months and not reached in older patients versus 12.0 and 18.1 months in younger patients. These findings demonstrate mosunetuzumab is effective and well-tolerated across age groups in patients with R/R FL. Additional studies are warranted to further evaluate the safety and efficacy of mosunetuzumab in older patients with B-NHL.
引用
- Thiruvengadam SK, Popplewell LL, Herrera AF, et al. Mosunetuzumab is effective and well tolerated in older patients with relapsed/refractory follicular lymphoma: Subgroup analysis of a phase I/II study. Br J Haematol. 2025. PMID: 41254806. doi:10.1111/bjh.70212
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。